First-time disclosures session at ACS Fall 2025 reveals diverse candidates for treating sickle cell disease, heart failure, ...

Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

There is no cure for congenital erythropoietic porphyria, but after years of work and patient collaboration, a potential drug ...

Stroke often results in persistent gait impairments, limiting mobility and reducing quality of life. This study evaluated FAST walk, a novel electromyography-triggered system that combines ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...